Impact of extracorporeal cytokine absorber and continuous real replacement therapy on plasma drug levels of Meropenem, Linezolid and Anidulafungin in critically ill surgical patients.

Impact of extracorporeal cytokine absorber and continuous real replacement therapy on plasma drug levels of Meropenem, Linezolid and Anidulafungin in critically ill surgical patients. - CADLAM-study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023684

Enrollment

Registered

2023-01-30

Start date

2017-12-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A41

Interventions

Group 1: Patients with septic shock, treated with CRRT for at least 48h and cytokine absorber for exact 48h (2 cycles á 24h) Group 2: Patients with septic shock, treated with CRRT without cytokine ab

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Septic Shock with Indikation for renal replacement therapy

Exclusion criteria

Exclusion criteria: -Age 200 mg/d -Low immunofunction (CD4 <200 or neutropenia <1000/µl) -Pregnancy or breast feeding patients -AIDS (<200 CD4/µl) -Terminal heart, real and/or hepatic failure

Design outcomes

Primary

Measure	Time frame
Elimination of antibiotics by the cytokine absorber and measurement of the difference of the drug level between both study arms. Observation period 96h. Measuring times: Expected maximum and minimum level.	—

Secondary

Measure	Time frame
- Length of Stay in ICU and hospital. Observation period 60 days	—

Countries

Germany

Contacts

Public ContactMagnus Kaffarnik

Charite - Universitätsmedizin Berlin, Campus Virchow Klinik für Allgemein, Viszeral- und Transplantationschirurgie

mkaffarnik@posteo.de+40(0)30450652235

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026